- 50% of All Evaluable Patients in Phase I Study Receiving Combination of Bavituximab Plus Chemotherapy Achieved Objective Tumor Response or Stable
Disease - - 100% of Evaluable Patients to Date in Ongoing Phase II Breast Cancer
Study Showing Objective Tumor Response or Stable Disease -
CHICAGO and TUSTIN, Calif., June 2 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that results from a Phase I clinical trial of its lead anti-phosphatidylserine (anti-PS) antibody bavituximab in combination with chemotherapy in patients with advanced cancer were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting. The Phase I data indicated that half of evaluable patients in the trial achieved objective tumor response or stable disease after eight weeks of dosing. The Phase I study results also showed that the safety profile of bavituximab and chemotherapy appeared consistent with chemotherapy alone and that the pharmacokinetic properties of bavituximab were not impacted by co- administration with conventional chemotherapies.
Separately, Peregrine reported an update from its ongoing Phase II
trial evaluating bavituximab plus docetaxel in advanced breast cancer.
Enrollment of an initial group of 15 patients in the two-stage Phase II
study was recently completed. Of the 11 evaluable patients to date, none
have experienced any measureable tumor growth or disease progression, with
five of the 11 evaluable patients achieving a partial tumor response. All
enrolled patients are continuing to receive treatment and are being
evaluated regularly for tumor response according to RECIST criteria. The
primary objective of the multi-center, open
|SOURCE Peregrine Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved